Icomix (Helium, Carbon Monoxide)

Helium’s very low molecular weight and density decrease turbulence in the large airways, promoting a smoother, laminar flow that lessens the effort required to breathe. Carbon monoxide binds reversibly to hemoglobin and influences cellular signaling pathways, notably inhibiting pro‑inflammatory transcription factors, which can reduce inflammatory injury in the lungs. Together, the gases provide both physical and biochemical mechanisms that aid respiratory function.

The dosage of Icomix is determined by the prescribing clinician based on the patient’s condition, age, weight, and the required fraction of inspired oxygen. Administration is typically performed using calibrated delivery systems that control the concentration of helium and carbon monoxide in the inhaled mixture. Exact dosing regimens, flow rates, and treatment duration must be individualized and documented in the patient’s medical record.

Safety data for Icomix in pregnant or lactating individuals are limited. Because carbon monoxide can cross the placenta and affect fetal oxygen delivery, the product is generally used only when the potential benefit outweighs the risk and under strict medical supervision. Breastfeeding mothers should consult their healthcare provider, as the gas may be exhaled and potentially affect the infant. Clinical judgment is essential.

To place an order, visit the product page for Icomix on the GNH India website (gnhindia.com) and submit an enquiry specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details—including any cold‑chain requirements—and assists with import documentation.

Compared with standard oxygen therapy, Icomix offers the advantage of helium’s low density, which reduces airway resistance and can improve ventilation in obstructive conditions where high‑flow oxygen alone is insufficient. Unlike pure helium‑oxygen mixtures, the addition of carbon monoxide provides anti‑inflammatory effects that may benefit certain inflammatory lung pathologies. However, the presence of carbon monoxide requires careful monitoring of carboxyhemoglobin levels, a consideration not needed with ordinary oxygen or heliox alone.

Icomix cylinders should be stored at ambient temperature, ideally below 25 °C, in a well‑ventilated, dry area away from direct sunlight and heat sources. Keep cylinders upright and secured to prevent tipping. Ensure that the storage area complies with local regulations for compressed gases and that only trained personnel handle the product. Regularly inspect cylinders for damage or leaks before use.

Icomix is delivered via inhalation using a calibrated gas delivery system, such as a ventilator circuit, mask, or specialized inhalation device. The system mixes the helium‑carbon monoxide gas with oxygen to achieve the prescribed fraction of inspired oxygen and gas concentration. Administration is performed under continuous monitoring of respiratory parameters, oxygen saturation, and, when relevant, carboxyhemoglobin levels to ensure safety and therapeutic efficacy.

The most serious risks include carbon monoxide poisoning, which can lead to elevated carboxyhemoglobin levels, severe hypoxemia, and potentially life‑threatening cardiovascular events. Methemoglobinemia, arrhythmias, and respiratory depression are also rare but critical complications. Prompt recognition of symptoms such as confusion, chest pain, cyanosis, or sudden drop in oxygen saturation is essential, and immediate medical intervention should be initiated if these occur.

Icomix is contraindicated in patients with known hypersensitivity to carbon monoxide or helium, those with significant hemoglobinopathies such as methemoglobinemia, and individuals with severe anemia where additional carbon monoxide binding could impair oxygen transport. It should also be avoided in patients receiving other carbon monoxide‑releasing agents or in settings where adequate monitoring of carboxyhemoglobin cannot be ensured. Clinical assessment is required before initiating therapy.